Tags

Type your tag names separated by a space and hit enter

Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children.
J Infect Dis 2006; 194(8):1032-9JI

Abstract

BACKGROUND

Two doses of trivalent inactivated influenza vaccine (TIV) are recommended for children <9 years old receiving vaccine for the first time, but compliance is suboptimal. This study assessed the need for a second dose of TIV in this age group.

METHODS

In this prospective, open-label study, 232 influenza vaccine-naive 5-8-year-olds enrolled in a health maintenance organization received 2 doses of TIV in fall 2004. Serum for antibody titer measurement was obtained at 3 time points (n = 222). Parents completed diaries for 5 days.

RESULTS

Both doses of vaccine were well tolerated. The strongest predictor of a protective antibody response (> or =1 : 40) after 1 dose of TIV was baseline seropositive status. In multivariate analysis adjusting for age, sex, and baseline serostatus, the proportion of children with protective antibody responses was significantly higher after 2 doses than after 1 dose of TIV for each antigen (P < .001, for A/H1N1; P = .01, for A/H3N2; P < .001, for B). Age and sex were not independently predictive of a protective antibody response. Over one-third of children had antibody responses <1:40 for the type B vaccine component, even after 2 doses.

CONCLUSIONS

The present study supports the need for 2 doses of TIV in 5-8-year-olds receiving TIV for the first time. Efforts to increase compliance with the 2-dose recommendation are warranted.

Authors+Show Affiliations

Program for Appropriate Technology in Health, School of Medicine, University of Washington, Seattle, Seattle, WA 98107, USA. kneuzil@path.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

16991077

Citation

Neuzil, Kathleen M., et al. "Immunogenicity and Reactogenicity of 1 Versus 2 Doses of Trivalent Inactivated Influenza Vaccine in Vaccine-naive 5-8-year-old Children." The Journal of Infectious Diseases, vol. 194, no. 8, 2006, pp. 1032-9.
Neuzil KM, Jackson LA, Nelson J, et al. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children. J Infect Dis. 2006;194(8):1032-9.
Neuzil, K. M., Jackson, L. A., Nelson, J., Klimov, A., Cox, N., Bridges, C. B., ... Shay, D. (2006). Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children. The Journal of Infectious Diseases, 194(8), pp. 1032-9.
Neuzil KM, et al. Immunogenicity and Reactogenicity of 1 Versus 2 Doses of Trivalent Inactivated Influenza Vaccine in Vaccine-naive 5-8-year-old Children. J Infect Dis. 2006 Oct 15;194(8):1032-9. PubMed PMID: 16991077.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children. AU - Neuzil,Kathleen M, AU - Jackson,Lisa A, AU - Nelson,Jennifer, AU - Klimov,Alexander, AU - Cox,Nancy, AU - Bridges,Carolyn B, AU - Dunn,John, AU - DeStefano,Frank, AU - Shay,David, Y1 - 2006/09/11/ PY - 2006/02/27/received PY - 2006/05/03/accepted PY - 2006/9/23/pubmed PY - 2006/11/15/medline PY - 2006/9/23/entrez SP - 1032 EP - 9 JF - The Journal of infectious diseases JO - J. Infect. Dis. VL - 194 IS - 8 N2 - BACKGROUND: Two doses of trivalent inactivated influenza vaccine (TIV) are recommended for children <9 years old receiving vaccine for the first time, but compliance is suboptimal. This study assessed the need for a second dose of TIV in this age group. METHODS: In this prospective, open-label study, 232 influenza vaccine-naive 5-8-year-olds enrolled in a health maintenance organization received 2 doses of TIV in fall 2004. Serum for antibody titer measurement was obtained at 3 time points (n = 222). Parents completed diaries for 5 days. RESULTS: Both doses of vaccine were well tolerated. The strongest predictor of a protective antibody response (> or =1 : 40) after 1 dose of TIV was baseline seropositive status. In multivariate analysis adjusting for age, sex, and baseline serostatus, the proportion of children with protective antibody responses was significantly higher after 2 doses than after 1 dose of TIV for each antigen (P < .001, for A/H1N1; P = .01, for A/H3N2; P < .001, for B). Age and sex were not independently predictive of a protective antibody response. Over one-third of children had antibody responses <1:40 for the type B vaccine component, even after 2 doses. CONCLUSIONS: The present study supports the need for 2 doses of TIV in 5-8-year-olds receiving TIV for the first time. Efforts to increase compliance with the 2-dose recommendation are warranted. SN - 0022-1899 UR - https://www.unboundmedicine.com/medline/citation/16991077/Immunogenicity_and_reactogenicity_of_1_versus_2_doses_of_trivalent_inactivated_influenza_vaccine_in_vaccine_naive_5_8_year_old_children_ L2 - https://academic.oup.com/jid/article-lookup/doi/10.1086/507309 DB - PRIME DP - Unbound Medicine ER -